SS18L2 Inhibitors

Chemical inhibitors of SS18L2 can disrupt its function through various mechanisms by targeting the pathways and cellular processes the protein is involved in. Palbociclib, Ribociclib, and Abemaciclib are CDK4/6 inhibitors that can inhibit the cell cycle's G1-S phase transition, a critical point where SS18L2 is likely to be active in its role in transcription regulation. By blocking this transition, these inhibitors can restrict the cellular context in which SS18L2 operates, limiting its ability to contribute to the transcriptional machinery. Similarly, Trametinib, Cobimetinib, Vemurafenib, Dabrafenib, Selumetinib, Binimetinib, and Encorafenib are designed to interfere with the MEK/ERK pathway or the BRAF protein within that pathway. By inhibiting these signaling molecules, the activity of downstream transcription factors, which might interact with SS18L2, is diminished, leading to an inhibition of SS18L2's potential role in transcriptional regulation.

Furthermore, Afatinib and Lapatinib are EGFR inhibitors that can downregulate the EGFR signaling pathway. EGFR signaling is known to modulate various cellular processes, including the activity of transcription factors that could be associated with SS18L2. By inhibiting EGFR and HER2, Lapatinib ensures a decrease in the activity of transcriptional regulators that SS18L2 might work alongside within cellular signaling. Consequently, these chemical inhibitors collectively serve to disrupt the pathways and processes that are essential for SS18L2's functional contribution to transcription regulation, effectively inhibiting the protein's activity without affecting its expression or the transcription of its gene.